FDA Approvals News 17 October 2025

Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) ripped higher again on 5 December 2025, extending one of the most dramatic biotech rallies of the year after positive epilepsy data and a favorable pre‑NDA meeting with the FDA. By the closing bell

6 December 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) extended its remarkable 2025 rally on Friday, December 5, with shares surging almost 40% intraday after the company reported a double dose of good news: a pivotal epilepsy trial stopped early for efficacy and

5 December 2025

Biotech Stocks · Epilepsy Research · FDA Approvals · Investment News · NASDAQ:PRAX · Pharmaceutical Industry

Eli Lilly (LLY) Stock Today, 4 December 2025: Zepbound Price Cuts, Jaypirca FDA Win and New $1,200–$1,500 Targets

Date: 4 December 2025 Eli Lilly stock at a glance Eli Lilly and Company (NYSE: LLY) is trading around $1,030–$1,040 per share on 4 December 2025, down roughly 1% on the session after slipping from about $1,046 in the previous

4 December 2025

FDA Approvals · Investment Analysis · NYSE:LLY · Pharmaceuticals · Price Targets · Stock Market

Merck (MRK) Stock on December 2, 2025: Dividend Hike, FDA Wins and Fresh Wall Street Targets

Merck & Co., Inc. (NYSE: MRK) is wrapping up 2025 with a flurry of news that matters to shareholders: a bigger dividend, new analyst price targets, fresh regulatory approvals for its cancer blockbuster Keytruda, and high‑profile acquisitions aimed at life

2 December 2025

Dividends · FDA Approvals · NYSE:MRK · Pharmaceuticals · Stock Market · Wall Street Analysis

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Rallies on Nov. 11, 2025: FDA Approves New Keytruda Companion Diagnostic; Fresh SITC Combo Data, and Dow Momentum

Published: November 11, 2025 At a glance (today) Market move: MRK helps lead the Dow’s advance By early afternoon Tuesday, Merck & Co. (NYSE: MRK) shares were up about 3.9%, helping lead the Dow Jones Industrial Average higher; Nike and

11 November 2025

Cancer Research · FDA Approvals · Immunotherapy · NYSE:MRK · Pharma News · Stock Market

NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

Recent FDA Approval and Market Reaction NeurAxis’s Oct. 24, 2025 announcement of FDA 510(k) clearance for its PENFS device immediately grabbed market attention. The clearance authorizes use in adults (8 years and up) for functional abdominal pain associated with FD

24 October 2025

Biotechnology · FDA Approvals · Investment News · Medical Devices · NASDAQ:NRXS · Stock Market

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Shares Skyrocket 350% on FDA-Approved Drug Launch – What’s Next?

Scienture’s unprecedented Oct. 23 rally was driven by the commercial rollout of Arbli, its first revenue-generating product. The company’s press release on Oct. 23 confirmed that it began sales and shipped first customer orders for Arbli (losartan suspension), immediately triggering

24 October 2025

Company Analysis · FDA Approvals · Investment Trends · NASDAQ:SCNX · Pharma News · Stock Market

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

SCNX Stock Soars on Arbli Launch News Scienture’s stock has been on a rollercoaster in late October amid excitement over Arbli’s rollout. The initial catalyst came on October 16, 2025, when the company announced Arbli™ was available through major wholesalers

23 October 2025

FDA Approvals · Investment News · Market Trends · Pharmaceuticals · Stock Market

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Stock Performance and Recent Rally Replimune’s stock has been extremely volatile in 2025. It soared on Oct. 20 after the FDA acceptance news: shares nearly doubled from about $4.50 to $8.94 that day marketbeat.com. (On Oct 21, REPL was trading

21 October 2025

Biotech News · FDA Approvals · Financial Markets · Investment Analysis · NASDAQ:REPL · Stock Market

Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Stock Performance & Analyst Consensus Intuitive’s stock has been volatile in 2025. It gained ground last week on optimism (e.g. up ~2.7% on Oct. 17) and now sits around $446 investing.com marketbeat.com. Over the past year, the price swung between

19 October 2025

FDA Approvals · Healthcare Stocks · Investment Strategies · Medical Technology · NASDAQ:ISRG · Stock Market

ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion

Key Facts – October 18, 2025 Stock Soars on Breakthrough News and Funding Boost ATAI’s stock price surged in the last few days amid a flurry of good news. Shares jumped 17.7% on Friday (Oct 17) alone, finishing at $6.45

18 October 2025

Biotech · FDA Approvals · Investment · NASDAQ:ATAI · Pharma News · Stock Market

Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

In summary, Artiva Biotherapeutics stock has erupted in October 2025 on the back of a major FDA Fast Track win and renewed optimism around its NK-cell therapy for RA. The latest developments – from surging share price and volume to

17 October 2025

Biotech News · FDA Approvals · Financial Analysis · Investment Strategies · NASDAQ:ARTV · Stock Market

FDA Approvals News 17 October 2025 - 6 December 2025